OPEN ACCESS

Prevalence of *Chlamydia trachomatis* infection in the general population of women in Qatar

Asma Al-Thani,¹ Hanan Abdul-Rahim,¹ Enas Alabsi,¹ Haneen N Bsaisu,¹ Pascale Haddad,² Ghina R Mumtaz,² Laith J Abu-Raddad^{2,3,4}

Arabic Abstract translation

¹Department of Health Sciences, College of Arts and Sciences, Qatar University, Doha, Qatar

²Infectious Disease Epidemiology Group, Weill Cornell Medical College—Qatar, Cornell University, Qatar Foundation—Education City, Doha, Qatar

³Department of Public Health, Weill Cornell Medical College, Cornell University, New York, New York, USA

⁴Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

Correspondence to

Dr Asma Ali J F Al-Thani, PhD, Department of Health Sciences, College of Arts and Sciences, Qatar University, P.O. Box 2713, Doha 2713, Qatar; aaja@qu.edu.qa

Received 14 April 2013

Revised 18 June 2013

Accepted 23 June 2013

Published Online First

17 July 2013

Open Access
Scan to access more
free content

To cite: Al-Thani A, Abdul-Rahim H, Alabsi E, et al. Sex Transm Infect 2013;89:iii57–iii60.

ABSTRACT

Objectives The Arabian Gulf region has limited epidemiological data related to sexually transmitted infections. The objective of this study was to estimate the prevalence of *Chlamydia trachomatis* infection among general population women in Doha, Qatar.

Methods Endocervical swabs were collected from healthy women attending primary healthcare centres in Doha, June–December 2008. The specimens were tested for *C trachomatis* by a commercially available PCR-based assay. Data on basic socio-demographic characteristics, medical history and sexual behaviour were obtained using self-administered questionnaires. The prevalence of *C trachomatis* and of background variables were stratified by nationality, Qatari nationals versus non-Qatari residents.

Results A total of 377 women were enrolled in the study, out of whom 351 (37.9% Qataris, 62.1% non-Qataris) were tested for the presence of *C trachomatis* in their specimens. The mean age of participants was 41.2 years, and the vast majority (93%, 95% CI 90.3 to 95.7) were married. The mean age at sexual debut was significantly lower among Qatari women compared with non-Qatari women (19.2 vs 22.2 years, respectively $p < 0.001$), but the mean number of reported lifetime sexual partners (1.1 partner) was nearly the same in both groups ($p = 0.110$). The prevalence of *C trachomatis* infection was 5.3% among Qatari women and 5.5% among non-Qatari women, with no statistically significant difference between both groups ($p = 0.923$).

Conclusions The prevalence of *C trachomatis* among women was higher than expected, with no significant difference between Qatari nationals and expatriate residents. The higher prevalence may reflect, in part, the limited access to and use of chlamydia screening and management.

INTRODUCTION

Data on the prevalence of *Chlamydia trachomatis* infection in the Middle East and North Africa (MENA) region remain scarce due to its limited research capacity and sociocultural sensitivity around sexually transmitted infections (STIs).^{1 2} This challenge is further compounded by methodological limitations in available studies and by the logistical difficulty in conducting STI studies among women.² Considering that *C trachomatis* is one of the most common curable bacterial STIs worldwide,³ and given its complications in infected women in terms of pelvic inflammatory disease, infertility and ectopic pregnancy among others,³ there is a need to address the invisible and poorly quantified disease burden of this infection in this part of the world. Against this background, the

objective of the present study was to estimate the prevalence of *C trachomatis* infection among general population women in Qatar.

METHODOLOGY

Study design and participants

This was a cross-sectional study on healthy asymptomatic ever-married women attending eight women's primary healthcare centres in the capital city, Doha, for a routine Pap smear examination during the period June to December 2008. A component of this study was focused on studying human papillomavirus epidemiology, and therefore, centres were considered only if Pap smear examination was offered. More than 70% of the total population of Qatar are non-Qatari,⁴ but Qataris were the primary target population for this study. Based on the advice of the Qatar Supreme Council of Health, these centres were chosen as they are frequented by Qatari nationals and offer Pap smear examination. The centres represent the core of primary healthcare services in Qatar serving over a million attendees per year within the women's clinics and the other clinics. All Qatari and resident non-Qatari women have access to these centres and the services are covered by the national health insurance programme. All the centres are in urban settings, and they cover both primary care as well as follow-up services.

Pregnant women were excluded. Study participants were enrolled by the attending physician and filled a self-administered questionnaire, which included data on sociodemographic and lifestyle indicators, reproductive and medical history and sexual behaviour. Only few questions about sexual behaviour were included, due to the sensitivity of this issue among this population. The study was approved by the Hamad Medical Corporation Research Committee, and all participants signed informed consent forms prior to enrolment in the study.

Biological sample collection and laboratory analysis

Endocervical swabs were collected by the attending physician. DNA extraction was performed, followed by PCR, using the commercially available *Chlamydia trachomatis* Real-TM PCR kit (Sacace Biotechnologies, Italy).

Data analysis

Cross-tabulations between the different background variables, as well as the biomarker for *C trachomatis* infection, and nationality (Qatari vs non-Qatari) were performed in order to describe the

characteristics of the study population. The prevalence of *C trachomatis* was also stratified by the sociodemographic and lifestyle indicators, reproductive and medical history factors and sexual behaviour characteristics for the Qatari versus non-Qatari women. The χ^2 test or the Fisher's exact test (for categorical variables) and the student t test (for continuous variables) were used to determine statistical significance in these associations. ORs for bivariate associations between the background variables and a positive *C trachomatis* test were derived using logistic regression. IBM-SPSS (Statistical Packages for the Social Sciences) V21.0 was used for all statistical analyses. The statistical significance was set at $p < 0.05$.

RESULTS

A total of 377 women were enrolled in the study, out of whom 351 (37.9% Qataris, 62.1% non-Qataris) were tested for the presence of *C trachomatis* in their specimens. The characteristics of tested and non-tested women were compared. No significant differences were found except for educational level ($p = 0.010$), where a higher percentage of those who took the test had a college degree compared with those who did not. Table 1 describes the characteristics of the study population who were tested for the presence of *C trachomatis*, stratified by nationality. The mean age of the participants was 41.2 years, and the vast majority (93.0%; 95% CI 90.3 to 95.7) were currently married. The proportion of women with no educational attainment was significantly higher ($p < 0.001$) among Qataris (35.9%) compared with non-Qataris (8.3%). Only a small fraction of the participants smoked (5.8%; 95% CI 3.3 to 8.3). The vast majority of the participants had children (95.7%; 95% CI 93.6 to 97.8); 72.5% of Qataris had more than four children compared with 37.2% of non-Qataris ($p < 0.001$).

Almost all respondents reported no prior history of a sexually transmitted disease; 7.4% (95% CI 4.7 to 10.3) had a family history of cervical cancer; 92.6% (95% CI 89.7 to 95.4) were not using oral contraceptives at the time of the study and 14.2% (95% CI 10.5 to 18.0) had regular Pap smear tests, with no statistically significant differences for these characteristics between the two nationality groups. The mean age at sexual debut was significantly lower among Qatari women (19.2 vs 22.2 years; $p < 0.001$), but the mean number of reported lifetime sexual partners (1.1 partner) was nearly the same for both groups ($p = 0.110$). Less than 10% of these women reported more than one lifetime sexual partner, and less than 1% had more than two partners. Nineteen women tested positive for *C trachomatis* indicating an overall prevalence of 5.4% (95% CI 3.0 to 7.8). The prevalence of *C trachomatis* was 5.3% among Qatari women and 5.5% among non-Qatari women, with no statistically significant difference between the two groups ($p = 0.923$).

Analyses of ORs were conducted to identify the different sociodemographic and lifestyle indicators, reproductive and medical history factors and sexual behaviour characteristics associated with a positive *C trachomatis* test. No statistically significant associations were found with any of the variables, probably reflecting the small number of those who tested positive. We also found no statistically significant differences in the prevalence of *C trachomatis* stratified by the sociodemographic and lifestyle indicators, reproductive and medical history factors and sexual behaviour characteristics for the Qatari versus non-Qatari women.

DISCUSSION

We documented a considerable prevalence of *C trachomatis* infection among women attending primary healthcare centres in Qatar. The prevalence of about 5% is broadly comparable with

reported figures in the United Arab Emirates⁵ and Kuwait⁶ within the Arabian Gulf region, in other MENA countries,² as

Table 1 Characteristics of the study population by nationality, women attending women's primary healthcare centres, Doha, Qatar, 2008

	Qatari (N=133) n (%)*	Non-Qatari (N=218) n (%)*	Total (N=351) n (%)*	p Value
Sociodemographic and lifestyle indicators				
Age				
20–29	14 (10.7)	35 (16.1)	49 (14.0)	
30–39	33 (25.2)	67 (30.9)	101 (28.9)	
40–49	54 (41.2)	74 (34.1)	128 (36.7)	
≥50	30 (22.9)	41 (18.9)	71 (20.3)	0.221
Mean (SD)	42.45 (9.43)	40.52 (10.21)	41.24 (9.96)	0.079
Current marital status				
Married	112 (86.2)	207 (97.2)	319 (93.0)	
Non-married	18 (13.8)	6 (2.8)	24 (7.0)	<0.001
Educational level				
None	46 (35.9)	18 (8.3)	64 (18.6)	
School	54 (42.2)	71 (32.9)	125 (36.3)	
College	28 (21.9)	127 (58.8)	155 (45.1)	<0.001
Smoking				
Yes	4 (3.1)	16 (7.4)	20 (5.8)	
No	126 (96.9)	200 (92.6)	326 (94.2)	0.095
Reproductive and medical history				
Number of children				
0	6 (4.6)	9 (4.1)	15 (4.3)	
1–3	30 (22.9)	128 (58.7)	158 (45.3)	
≥4	95 (72.5)	81 (37.2)	176 (50.4)	<0.001
Mean (SD)	5.44 (3.05)	3.21 (1.93)	4.05 (2.64)	<0.001
Previous miscarriage				
0	72 (54.5)	131 (61.2)	203 (58.7)	
1–2	45 (34.1)	69 (32.2)	114 (32.9)	
≥3	15 (11.4)	14 (6.5)	29 (8.4)	0.227
Mean (SD)	0.95 (1.40)	0.69 (1.16)	0.79 (1.26)	0.056
Current oral contraceptive use				
Yes	8 (6.2)	17 (8.2)	25 (7.4)	
No	121 (93.8)	190 (91.8)	311 (92.6)	0.495
STD history				
Yes	0 (0.0)	1 (0.5)	1 (0.3)	
No	132 (100.0)	211 (99.5)	343 (99.7)	0.999
Frequency of Pap smear				
Never	37 (28.9)	68 (32.5)	105 (31.2)	
Regular	13 (10.2)	35 (16.7)	48 (14.2)	
Irregular	78 (60.9)	106 (50.7)	184 (54.6)	0.118
Family history of cervical cancer				
Yes	8 (6.1)	18 (8.3)	26 (7.4)	
No	124 (93.9)	198 (91.7)	323 (92.6)	0.434
Sexual behaviour				
Age of sexual debut				
≤15 years	30 (23.3)	21 (10.0)	51 (15.0)	
>15 years	99 (76.7)	190 (90.0)	289 (85.0)	0.001
Mean (SD)	19.91 (5.17)	22.15 (5.19)	21.31 (5.29)	<0.001
Number of years since sexual debut				
<10	24 (18.3)	58 (27.0)	82 (23.7)	
10–19	38 (29.0)	79 (36.7)	117 (33.8)	
20–29	42 (32.1)	46 (21.4)	88 (25.4)	
≥30	27 (20.6)	32 (14.9)	59 (17.1)	0.026
Mean (SD)	19.92 (11.06)	17.00 (10.06)	18.08 (10.52)	0.012

Continued

Table 1 Continued

	Qatari (N=133) n (%)*	Non-Qatari (N=218) n (%)*	Total (N=351) n (%)*	p Value
Number of lifetime sexual partners				
1	115 (89.8)	205 (96.2)	320 (93.8)	
2	12 (9.4)	6 (2.8)	18 (5.3)	
≥3	1 (0.8)	2 (0.9)	3 (0.9)	0.023
Mean (SD)	1.11 (0.34)	1.05 (0.30)	1.07 (0.31)	0.110
<i>Chlamydia trachomatis</i> infection				
<i>Chlamydia trachomatis</i> results				
Negative	126 (94.7)	206 (94.5)	332 (94.6)	0.923
Positive	7 (5.3)	12 (5.5)	19 (5.4)	

NB: Numbers do not necessarily add up to the total because of missing values, and numbers in bold represent significance at $p < 0.05$.

STD, sexually transmitted disease.

*Column percentages.

well as globally in North America,^{7–8} Europe,^{9–10} Asia,^{11–12} Oceania^{13–14} and sub-Saharan Africa.¹⁵ Nevertheless, the prevalence tends to be at the higher side of the global range particularly in view of the average age of the participants. This finding was not expected considering the prevailing sexually conservative norms and low reported sexual-risk behaviour in the MENA region.^{2–16}

This result, however, may not be interpreted as necessarily higher than expected levels of sexual risk behaviour. The fact that there are no formal *C. trachomatis* screening programmes, or any specific bacterial STIs prevention and treatment programmes, may have contributed to the higher prevalence. As seen in other populations globally, limited active chlamydia diagnosis and specific treatment can lead to surprisingly high levels of prevalence, as a consequence of the asymptomatic nature of this infection and its persistence for months or years if untreated.^{17–18} The high sensitivity of the employed microbiological assay may have also contributed to a higher positivity rate,^{15–19–20} as well as the enforced restricted-access to antibiotics in Qatar in view of an ecological correlation between antibiotics use and lower prevalence.²¹ Since the study participants, irrespective of their nationality, have access to the services offered by the national healthcare system, it is not likely that differences in access to healthcare can explain the difference in prevalence among Qatari versus non-Qatari women. Regardless, the difference was small and not statistically significant.

On the other hand, the observed prevalence suggests that risks for acquiring the infection are present, though not necessarily through the women's own behaviour. The women likely acquired the infection from their spouses, an observation supported by the overall pattern of STIs in MENA.^{2–16} For example, although women are estimated to account for 9% of people engaged in high-risk behaviour in Morocco, they contribute to about 50% of new HIV infections.²² Similarly, 97%²³ and 76%^{24–25} of notified HIV-infected women in Saudi Arabia and Iran, respectively, have acquired the infection from their husbands. In view of the high mobility of the population in Qatar and the fact that more than 70% are expatriates,⁴ the infection transmission networks likely transcend the borders of this country.

We recruited women attending healthcare centres, and such a population may not be representative of the female population in Qatar. Reporting bias may have affected our study with the stigma surrounding STIs in this population. Chlamydia prevalence tends to be low in general population groups, and the

employed PCR kit has not been validated in our study population, thereby potentially undermining the positive predictive value of the diagnostic test.²⁶ With the small number of infections in the sample, and the few sexual behaviour measures collected, our study also lacked an analytical design to examine specific risk factors for the infection. The predictors of infection and the age distribution of infection among these women could strikingly be different from those in other settings given the differences in sociocultural context and sexual networking. Future studies on *C. trachomatis* should consider larger sample sizes to allow for identification of the predictors of infection and should include testing for other STIs, such as gonorrhoea and herpes simplex virus type 2. This will add key data to our knowledge of STIs in this part of the world.

Despite these limitations, our study, the first of its nature in Qatar, is an endeavour to examine a neglected disease burden in spite of challenges limiting the conduct of such studies. Our findings highlight a disease burden that is largely not being dealt with, but should be addressed through targeted programmes for sexual health and STIs for both women and men. Such programmes need to be culturally sensitive and gender-specific to be acceptable and relevant, and should capitalise on the strengths of MENA's cultural traditions.²⁷ Considering the modest contribution of our study to informing specific policy and programming, further research on representative population samples and cost-effectiveness analyses are needed before specific screening and treatment programmes could be recommended. Opportunistic targeted screening could be a meaningful starting point, with potentially routine Pap smear testing as an entry point.

CONCLUSION

We documented higher than expected *C. trachomatis* prevalence in Qatar, possibly reflecting the limited specific diagnosis and treatment programmes. Our study highlights how the disease burden of STIs, even in a sexually conservative society, could be significant with the lack of STI-specific programmes. Since multiple STIs are curable, including *C. trachomatis*, detecting these infections and linking them with appropriate treatment channels could alleviate an unnecessary disease burden and its consequences in the population.

Key messages

- ▶ We found higher than expected prevalence of *Chlamydia trachomatis* infection among women attending primary healthcare centres in Qatar, with no significant difference in prevalence between Qatari nationals and expatriate residents.
- ▶ The observed prevalence may reflect the limited access and use of Chlamydia-specific screening and management.

Handling editor Jackie A Cassell

Acknowledgements The authors would like to thank Mrs. Moza Al-Khanji, Senior Laboratory Technician, Department of Health Sciences, Collage of Arts and Sciences at Qatar University, for her help in the conduct of the laboratory work. We would like also to thank the gynaecologists and nurses at the women's primary healthcare centres for their help in sample collection. Last but not least, we would like to thank all the women who participated in this study.

Contributors AA-T designed the study, developed the research methodology and led the data collection and interpretation of the results. EA and HNB did the laboratory work and were responsible for the data management. PH conducted most of the statistical analyses. GRM and LJA-R wrote the first draft of the article. All authors contributed to the interpretation of the findings and writing of the article.

Funding This work was funded by the Research Committee of the College of Arts and Sciences, Qatar University (QUUG-CAS-DHS-10/11-6); the Qatar National Research Fund (NPRP 4-924-3-251); and the Biostatistics, Epidemiology, and Biomathematics Research Core at the Weill Cornell Medical College—Qatar.

Competing interests None.

Patient consent Obtained.

Ethics approval Hamad Medical Corporation Research Committee.

Provenance and peer review Commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/3.0/>

REFERENCES

- McFarland W, Abu-Raddad LJ, Mahfoud Z, *et al.* HIV/AIDS in the Middle East and North Africa: new study methods, results, and implications for prevention and care. *AIDS* 2010;24:S1–4.
- Abu-Raddad L, Akala FA, Semini I, *et al.* Characterizing the HIV/AIDS epidemic in the Middle East and North Africa: time for strategic action. *Middle East and North Africa HIV/AIDS Epidemiology Synthesis Project. World Bank/UNAIDS/WHO Publication*. Washington, DC: The World Bank Press, 2010.
- World Health Organization. Initiative for Vaccine Research (IVR), Sexually Transmitted Diseases—Chlamydia trachomatis. [January 2113]. http://www.who.int/vaccine_research/diseases/soa_std/en/index1.html
- International Organization for Migration. *World migration: costs and benefits of international migration*. Geneva, Switzerland: International Organization for Migration, 2005.
- Ghazal-Aswad S, Badrinath P, Osman N, *et al.* Prevalence of Chlamydia trachomatis infection among women in a Middle Eastern community. *BMC Womens Health* 2004;4:3.
- Al-Sweih NA, Khan S, Rotimi VO. Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae among asymptomatic women attending the Capital Health region clinics in Kuwait. *Sex Transm Dis* 2011;38:793–7.
- Datta SD, Torrone E, Kruszon-Moran D, *et al.* Chlamydia trachomatis trends in the United States among persons 14 to 39 years of age, 1999–2008. *Sex Transm Dis* 2012;39:92–6.
- Fine D, Thomas KK, Nakatsukasa-Ono W, *et al.* Chlamydia positivity in women screened in family planning clinics: racial/ethnic differences and trends in the northwest U.S., 1997–2006. *Public Health Rep* 2012;127:38–51.
- Wilson JS, Honey E, Templeton A, *et al.* A systematic review of the prevalence of Chlamydia trachomatis among European women. *Hum Reprod Update* 2002;8:385–94.
- Paavonen J. Chlamydia trachomatis infections of the female genital tract: state of the art. *Ann Med* 2012;44:18–28.
- Imai H, Nakao H, Shinohara H, *et al.* Population-based study of asymptomatic infection with Chlamydia trachomatis among female and male students. *Int J STD AIDS* 2010;21:362–6.
- Yongjun T, Samuelson J, Qingsheng D, *et al.* The prevalence of sexually transmitted and other lower reproductive tract infections among rural women in Sichuan Province, China. *Southeast Asian J Trop Med Public Health* 2009;40:1038–47.
- Lewis D, Newton DC, Guy RJ, *et al.* The prevalence of Chlamydia trachomatis infection in Australia: a systematic review and meta-analysis. *BMC Infect Dis* 2012;12:113.
- Morgan J, Colonne C, Bell A. Trends of reported chlamydia infections and related complications in New Zealand, 1998–2008. *Sex Health* 2011;8:412–18.
- Chico RM, Mayaud P, Ariti C, *et al.* Prevalence of malaria and sexually transmitted and reproductive tract infections in pregnancy in sub-Saharan Africa: a systematic review. *JAMA* 2012;307:2079–86.
- Abu-Raddad LJ, Hilmi N, Mumtaz G, *et al.* Epidemiology of HIV infection in the Middle East and North Africa. *AIDS* 2010;24(Suppl 2):S5–23.
- Stamm WE. Chlamydia trachomatis infections of the adult. In: Holmes KK, Sparling FP, Stamm WE, Piot P, Wasserheit JN, Corey L, *et al.*, eds. *Sexually transmitted diseases*. 4th edn. New York, USA: McGraw Hill Medical, 2008:575–93.
- Toomey KE, Rafferty MP, Stamm WE. Unrecognized high prevalence of Chlamydia trachomatis cervical infection in an isolated Alaskan Eskimo population. *JAMA* 1987;258:53–6.
- Land JA, Van Bergen JE, Morre SA, *et al.* Epidemiology of Chlamydia trachomatis infection in women and the cost-effectiveness of screening. *Hum Reprod Update* 2010;16:189–204.
- Kuyper J, World Health Organization. Laboratory tests for the detection of reproductive tract infections. In: Jejeebhoy S, Koenig M, Elias C, eds. *Reproductive Tract Infections and Other Gynaecological Disorders: A Multidisciplinary Research Approach*. Cambridge, UK: Cambridge University Press, 2003:225–60.
- O'Rourke KM, Fairley CK, Samaranayake A, *et al.* Trends in Chlamydia positivity over time among women in Melbourne Australia, 2003 to 2007. *Sex Transm Dis* 2009;36:763–7.
- Mumtaz RG, Kouyoumjian PS, Hilmi N, *et al.* The distribution of new HIV infections by mode of exposure in Morocco. *Sex Transm Infect* 2013;89:iii49–56.
- Alrajhi AA, Halim MA, Al-Abdely HM. Mode of transmission of HIV-1 in Saudi Arabia. *Aids* 2004;18:1478–80.
- Ramezani A, Mohraz M, Gachkar L. Epidemiologic situation of human immunodeficiency virus (HIV/AIDS patients) in a private clinic in Tehran, Iran. *Arch Iran Med* 2006;9:315–18.
- Burrows D, Wodak A, WHO. Harm Reduction in Iran. Issues in national scale-up. Report for World Health Organization. 2005.
- Grimes DA, Schulz KF. Uses and abuses of screening tests. *Lancet* 2002;359:881–4.
- Abu-Raddad LJ, Sgaier SK, Mumtaz GR. HIV response in the Middle East and North Africa: an epidemic and its policy dilemmas. In: Smith R, ed. Washington, DC: Praeger Publishers, 2013.